Meta AnalysisID 2818
吲哚胺2,3-双加氧酶抑制剂作为单药或联合治疗在癌症患者中的应用：一项系统评价和Meta分析
CRD42022380377
The purpose of the present review and meta-analysis is to systematically investigate indole amine 2, 3 dioxygenase (IDO) inhibitors as mono or combination therapy in solid tumor patients. The specific objectives are as f
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2818
- Evidence Id
- 11376
- Core Evidence Id
- 11376
- Source Meta Analysis Id
- 2762
- Herb2 Meta Analysis Id
- HBMA002762
- Crd Id
- CRD42022380377
- Title
- Indoleamine 2, 3 dioxygenase (IDO) inhibitors as mono or combination therapy in cancer patients: A systematic review and Meta-analysis
- Review Question
- The purpose of the present review and meta-analysis is to systematically investigate indole amine 2, 3 dioxygenase (IDO) inhibitors as mono or combination therapy in solid tumor patients. The specific objectives are as follows: 1) To identify studies investigating indole amine 2, 3 dioxygenase (IDO) inhibitors as mono or combination therapy in solid tumors and their adverse events 2) To compare eligible studies on key study characteristics. 3) To extract relevant data from the studies identified during the systematic review process. 4) To evaluate the included studies through a study quality assessment. 5) To subject the extracted data to meta-analysis using a random effects model. 6) To explore possible causes of heterogeneity (I²>0) using subgroup analyses and meta-regression and test the robustness of the results using sensitivity analyses. 7) To discuss possible methodological limitations in the included studies and the present systematic review and meta-analysis. 8) To discuss the clinical implications of the results.
- Study Type Included
- We will include randomised clinical trials to assess the beneficial effects of the treatment and harms.
- Condition Being Studied
- Cancer
- Participant
- Inclusion: Adults (above 18 years of age) with solid tumour treated with IDO inhibitors Exclusion: Cancer patients not treated with IDO inhibitors, patients under 18, pregnancy or lactation
- Animal
- Human Disease Modelled
- Intervention
- Use of Indole amine 2, 3 dioxygenase (IDO) inhibitors as mono or combination therapy in cancer treatment
- Comparator Control
- Standard care or Placebo group
- Main Outcome
- The effectiveness of cancer treatment is measured using Overall Survival (OS) . Measures of effect
- Outcome Measure
- Additional Outcome
- Objective Response Rate(ORR), Progression-free survival (PFS), Objective Remission Rate, Disease Control Rate, reducing plasma kynurenine level, and adverse events
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Amines; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Indoles; Neoplasms; Tryptophan Oxygenase
- Contact
- Pardis Ahmadi [email protected]
- Organisational Affiliation
- Isfahan University of medical Sciences
- Funding Source
- This review was funded by the Isfahan University of Medical Sciences with project code 140172.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Iran
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-11-30
- Registration Date
- 2022-12-11
- Anticipated Start Date
- 2022-11-30
- Anticipated Completion Date
- 2023-03-01
- Title Cn
- 吲哚胺2,3-双加氧酶抑制剂作为单药或联合治疗在癌症患者中的应用：一项系统评价和Meta分析
- Title En
- Indoleamine 2, 3 dioxygenase (IDO) inhibitors as mono or combination therapy in cancer patients: A systematic review and Meta-analysis
- Bilingual Status
- complete